This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Winners & Losers: Gilead

Stocks in this article: cege amgn gild

Biotech stocks overall ticked up slightly Thursday, but one notable exception was Cell Genesys (CEGE), which sank 75% to 17 cents on word of a serious clinical setback.

The decline in Cell Genesys came after the company said it terminated a second study on its prostate cancer vaccine GVAX, and said it would cut 75% of its workforce.

Still, Cell Genesys did little to hurt the Nasdaq Biotechnology index, of which it's a component. The index added 3.3%, outperforming the broader market.

The Amex Biotechnology index added 2.1%. Components and biotech bellwethers Amgen (AMGN) and Celgene (CELG) added 1.6% and 1.5%, respectively.

Celgene (CELG) and Acceleron Pharma said they have initiated a midstage trial on an investigational bone loss therapy in patients with multiple myeloma. It will trigger a $5 million milestone payment from Celgene to Acceleron.

Following the close, earnings are expected from Gilead (GILD). Analysts surveyed by Thomson Reuters are looking for a profit of 49 cents a share on $1.32 billion in revenue. Gilead shares were up 5.9% ahead of quarterly results.

Elsewhere, Brean Murray and Merriman Curhan Ford initiated coverage on multiple small- to mid-cap health-care stocks.

Brean Murray began coverage on Mentor (MNT) with a hold rating. Shares were off by 1.5% at $15.82.

The firm also picked up coverage on Xtent (XTNT), NuVasive (NUVA) and Hansen Medical (HNSN) with buy ratings. Xtent shares were up 9.8%, and NuVasive gave up 2.2%. Hansen Medical gained 6.6%.

Meanwhile, Merriman Curhan Ford started Dendreon (DNDN) with a sell rating. The stock was down 1.7%, at $80.06. The firm began coverage on Ariad Pharma (ARIA) with a neutral rating. Shares rose 7.3% to $1.61.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,630.41 +273.54 1.58%
S&P 500 2,045.51 +32.62 1.62%
NASDAQ 4,727.5970 +83.2850 1.79%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs